These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 29214723

  • 1. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [Abstract] [Full Text] [Related]

  • 2. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Nov; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 4. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Nov; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 5. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG.
    J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
    [Abstract] [Full Text] [Related]

  • 6. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Jun; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 7. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

  • 8. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
    Boswood A, Gordon SG, Häggström J, Vanselow M, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T.
    J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M.
    J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).
    Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, Smith S, Patteson M, French AT, Culshaw GJ, Braz-Ruivo L, Estrada A, O'Sullivan ML, Loureiro J, Willis R, Watson P.
    J Vet Intern Med; 2012 Jan 20; 26(6):1337-49. PubMed ID: 23078651
    [Abstract] [Full Text] [Related]

  • 12. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR, Minors SL, O'Sullivan ML, Horne R.
    J Vet Intern Med; 2008 Jan 20; 22(4):897-904. PubMed ID: 18537880
    [Abstract] [Full Text] [Related]

  • 13. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N, Wall L, Nolte I, Raue J, Rumstedt K, Pilgram A, Sehn M, Rohn K, Bach JP.
    PLoS One; 2019 Jan 20; 14(10):e0223164. PubMed ID: 31581204
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ, French AT, Van Israël N, Smith SG, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J.
    J Small Anim Pract; 2005 Mar 20; 46(3):121-30. PubMed ID: 15789807
    [Abstract] [Full Text] [Related]

  • 15. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, Rumstedt K, Bach JP.
    BMC Vet Res; 2019 Jul 09; 15(1):237. PubMed ID: 31288807
    [Abstract] [Full Text] [Related]

  • 16. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S, Nolte I, Rumstedt K, Sehn M, Raue JF, Weiner F, Treese JS, Beyerbach M, Bach JP.
    BMC Vet Res; 2021 Sep 25; 17(1):310. PubMed ID: 34563187
    [Abstract] [Full Text] [Related]

  • 17. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS, Monteith G, Raheb S, Colpitts M, Fonfara S.
    Vet J; 2020 Sep 25; 263():105518. PubMed ID: 32928487
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
    Boswood A, Smith S, Patteson M.
    Vet Rec; 2011 Feb 26; 168(8):222. PubMed ID: 21493561
    [No Abstract] [Full Text] [Related]

  • 19. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 26; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 20. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D, Fry D.
    Compend Contin Educ Vet; 2011 Nov 26; 33(11):E1. PubMed ID: 22101450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.